NCT04752267
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Early Phase 1
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have available tumor tissue for submission to the sponsor obtained after the last anti-cancer therapy administered & obtained prior to study enrollment
Exclusions: Patients who have not received radiation therapy
https://ClinicalTrials.gov/show/NCT04752267